The Role of Co-Signaling Molecules in Psoriasis and Their Implications for Targeted Treatment

Psoriasis is a chronic, systemic immune-mediated inflammatory disease manifesting in the skin, joint or both. Co-signaling molecules are essential for determining the magnitude of the T cell response to the antigen. According to the function of co-signaling molecules, they can be divided into co-sti...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 12; p. 717042
Main Authors Liu, Suqing, Xu, Jinhua, Wu, Jinfeng
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 20.07.2021
Subjects
Co-inhibitory molecules
Co-stimulatory molecules
immunotherapy
Pharmacology
psoriasis
T lymphocytes
Online AccessGet full text

Cover

More Information
Summary:Psoriasis is a chronic, systemic immune-mediated inflammatory disease manifesting in the skin, joint or both. Co-signaling molecules are essential for determining the magnitude of the T cell response to the antigen. According to the function of co-signaling molecules, they can be divided into co-stimulatory molecules and co-inhibitory molecules. The role of co-signaling molecules in psoriasis is recognized, mainly including the co-stimulatory molecules CD28, CD40, OX40, CD27, DR3, LFA-1, and LFA-3 and the co-inhibitory molecules CTLA-4, PD-1, and TIM-3. They impact the pathological process of psoriasis by modulating the immune strength of T cells, regulating the production of cytokines or the differentiation of Tregs. In recent years, immunotherapies targeting co-signaling molecules have made significant progress and shown broad application prospects in psoriasis. This review aims to outline the possible role of co-signaling molecules in the pathogenesis of psoriasis and their potential application for the treatment of psoriasis.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Jian Gao, Second Affiliated Hospital of Dalian Medical University, China
Xin Li, Shanghai University of Traditional Chinese Medicine, China
Reviewed by: Sheng Wang, Fifth People’s Hospital of Suzhou, China
Juan Su, Central South University, China
This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2021.717042